Westbrook Rachel H, Yeoman Andrew D, Agarwal Kosh, Aluvihare Varuna, O'Grady John, Heaton Nigel, Penna Leonie, Heneghan Michael A
Institute of Liver Studies, King's College Hospital, National Health Service Foundation Trust, London, United Kingdom.
Liver Transpl. 2015 Sep;21(9):1153-9. doi: 10.1002/lt.24182.
Reports of pregnancy in liver transplantation (LT) patients have largely favorable outcomes. Concerns remain with regards to maternal and graft risk, optimal immunosuppression (IS), and fetal outcomes. We review all post-LT pregnancies at our center with regard to the outcomes and safety for the patient, graft, and fetus. A total of 117 conceptions occurred in 79 patients. Median age at conception was 29 years. Maternal complications included graft loss (2%), acute cellular rejection (ACR; 15%), pre-eclampsia/eclampsia (15%), gestational diabetes (7%), and bacterial sepsis (5%). ACR was significantly more common in those women who conceived within 12 months of LT (P = 0.001). The live birth rate was 73%. Prematurity occurred in 26 (31%) neonates, and 24 (29%) neonates were of low or very low birth weight. IS choice (cyclosporine versus tacrolimus) had no significant effect on pregnancy outcomes and complications. No congenital abnormalities occurred, and only 1 child born at 24 weeks had delayed developmental milestones. In conclusion, pregnancy following LT has a favorable outcome in the majority, but severe maternal risks remain. Patients should be counseled with regard to the above information so informed decisions can be made, and pregnancy must be considered high risk with regular monitoring by transplant clinicians and specialist obstetricians.
肝移植(LT)患者妊娠的报告大多显示出良好的结局。然而,对于母体和移植物风险、最佳免疫抑制(IS)以及胎儿结局仍存在担忧。我们回顾了本中心所有肝移植后妊娠患者的情况,包括患者、移植物和胎儿的结局及安全性。79例患者共发生117次妊娠。妊娠时的中位年龄为29岁。母体并发症包括移植物丢失(2%)、急性细胞排斥反应(ACR;15%)、先兆子痫/子痫(15%)、妊娠期糖尿病(7%)和细菌性败血症(5%)。ACR在肝移植后12个月内妊娠的女性中更为常见(P = 0.001)。活产率为73%。26例(31%)新生儿早产,24例(29%)新生儿为低体重或极低体重。免疫抑制方案的选择(环孢素与他克莫司)对妊娠结局和并发症无显著影响。未发生先天性异常,只有1例24周出生的儿童有发育迟缓。总之,肝移植后妊娠大多数结局良好,但母体仍存在严重风险。应向患者提供上述信息,以便做出明智的决定,并且必须将妊娠视为高风险情况,由移植临床医生和专业产科医生进行定期监测。